(Q54031367)

23 May 2018

title

Vinorelbine and cisplatin in metastatic breast cancer patients previously treated with anthracyclines. (English)

1 reference

23 May 2018

main subject

metastatic breast cancer

1 reference

1 reference

M Vassilomanolakis

1

1 reference

23 May 2018

G Koumakis

2

1 reference

23 May 2018

V Barbounis

3

1 reference

23 May 2018

M Demiri

4

1 reference

23 May 2018

H Pateras

5

1 reference

23 May 2018

A P Efremidis

6

1 reference

23 May 2018

publication date

1 September 2000

1 reference

23 May 2018

published in

Annals of Oncology

1 reference

23 May 2018

volume

11

1 reference

23 May 2018

issue

9

1 reference

23 May 2018

page(s)

1155-1160

1 reference

23 May 2018

Cancer of the breast: the past decade (first of two parts).

cites work

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008377724931

7 January 2021

Cancer of the breast: the past decade (second of two parts)

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008377724931

7 January 2021

A prospective randomized phase III trial comparing combination chemotherapy with cyclophosphamide, fluorouracil, and either doxorubicin or epirubicin. French Epirubicin Study Group

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008377724931

7 January 2021

Drugs ten years later: epirubicin.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008377724931

7 January 2021

Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008377724931

7 January 2021

Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008377724931

7 January 2021

A phase II study of the effectiveness of docetaxel (Taxotere) in women with advanced breast cancer previously treated with polychemotherapy. Hellenic Cooperative Interhospital Group in Oncology

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008377724931

7 January 2021

Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. 304 Study Group

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008377724931

7 January 2021

Paclitaxel as second and subsequent therapy for metastatic breast cancer: activity independent of prior anthracycline response

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008377724931

7 January 2021

Paclitaxel activity in heavily pretreated breast cancer: a National Cancer Institute Treatment Referral Center trial

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008377724931

7 January 2021

Interaction of vinblastine analogues with tubulin.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008377724931

7 January 2021

Phase II trial of weekly intravenous vinorelbine in first-line advanced breast cancer chemotherapy

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008377724931

7 January 2021

Intravenous vinorelbine as first-line and second-line therapy in advanced breast cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008377724931

7 January 2021

Docetaxel-cisplatin combination (DC) chemotherapy in patients with anthracycline-resistant advanced breast cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008377724931

7 January 2021

Management of breast cancer patients failing adjuvant chemotherapy with adriamycin-containing regimens

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008377724931

7 January 2021

Salvage therapies in women who fail to respond to first-line treatment with fluorouracil, epirubicin, and cyclophosphamide for advanced breast cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008377724931

7 January 2021

Paclitaxel activity in anthracycline refractory breast cancer patients.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008377724931

7 January 2021

A phase II study of paclitaxel in advanced breast cancer resistant to anthracyclines

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008377724931

7 January 2021

A phase II study of cis-diamminedichloroplatinum II for advanced breast cancer. Two dose schedules

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008377724931

7 January 2021

Cisplatin in the treatment of metastatic breast carcinoma: A prospective randomized trial of two dosage schedules

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008377724931

7 January 2021

Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: a Southwest Oncology Group study

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008377724931

7 January 2021

Phase II study of cisplatin and vinorelbine as first-line chemotherapy in patients with carcinoma of the uterine cervix

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008377724931

7 January 2021

Vinorelbine as first-line chemotherapy for metastatic breast carcinoma

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008377724931

7 January 2021

Infusional paclitaxel and weekly vinorelbine chemotherapy with concurrent filgrastim for metastatic breast cancer: high complete response rate in a phase I-II study of doxorubicin-treated patients

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008377724931

7 January 2021

Identifiers

DOI

10.1023/A:1008377724931

1 reference

23 May 2018

1 reference

23 May 2018